Weight loss treatment information and prices
Our GPs can help you start Mounjaro or Wegovy if treatment is right for you. Repeats are requested online and delivered to your door, with GP review and support built in.
Weight loss medication prices
Each price is for a 4-week medication supply, containing four once-weekly injections.
| 4 week supply | Price |
|---|---|
| Wegovy 0.25mg | £98.98 |
| Wegovy 0.5mg | £118.97 |
| Wegovy 1mg | £148.97 |
| Wegovy 1.7mg | £178.97 |
| Wegovy 2.4mg | £198.97 |
| Mounjaro 2.5mg | £168.97 |
| Mounjaro 5mg | £188.97 |
| Mounjaro 7.5mg | £248.97 |
| Mounjaro 10mg | £278.97 |
| Mounjaro 12.5mg | £288.97 |
| Mounjaro 15mg | £298.97 |
Prescribing, repeats and delivery
How treatment is prescribed and supplied
Medication is prescribed only where suitable after a GP consultation. If prescribed, it is delivered to your door, and repeat prescriptions can be requested online with GP review.
- 1Start with a GP consultationYour GP will assess your health, weight, current medicines and suitability before discussing treatment options.
- 2Prescription issued if suitableIf treatment is right for you, your GP issues a prescription and explains how to start safely.
- 3Medication delivered to your doorIf your GP prescribes treatment, your medication is usually delivered to your door within 1–2 days. Each 4-week supply contains four once-weekly injections.
- 4Request repeats onlineRepeat prescriptions can be requested through your DocTap account. A GP reviews each request and, if all is well, medication is delivered to your door at prices aligned with leading online pharmacies.
Treatment options
Mounjaro and Wegovy: what’s the difference?
Both are prescription-only, once-weekly injections used for medical weight loss. Your GP will help decide whether either is suitable, based on your health, current medicines, preferences and side-effect risk.
Wegovy
-
Active ingredient: Semaglutide
-
How it works: Wegovy is a GLP-1 receptor agonist. It acts on appetite and fullness signals, helping reduce hunger, food cravings and calorie intake.
-
Dose: Treatment usually starts at 0.25mg once weekly and is increased gradually if tolerated.
-
Evidence: In a major clinical trial, people taking Wegovy lost around 15% of their body weight on average over 68 weeks. Individual results vary.
-
Your GP will consider: Your weight, medical history, current medicines, diabetes or eye history, stomach or pancreas problems, pregnancy plans and side-effect risk.
Mounjaro
-
Active ingredient: Tirzepatide
-
How it works: Mounjaro is a dual GIP and GLP-1 receptor agonist. It acts on appetite, fullness and blood-sugar pathways, helping reduce hunger, cravings and calorie intake.
-
Dose: Treatment usually starts at 2.5mg once weekly and is increased gradually if tolerated.
-
Evidence: In a major clinical trial, people taking Mounjaro lost around 15–21% of their body weight on average over 72 weeks, depending on dose. Individual results vary.
-
Your GP will consider: Your weight, medical history, current medicines, diabetes treatment, stomach or pancreas problems, pregnancy plans and side-effect risk.
Eligibility is assessed based on the criteria below and the patient’s medical history
- Age reguirements
18 years or older. Treatment is not prescribed under 18. Caution is applied for patients over 75.
- BMI thresholds
BMI of 30 kg/m² or more, or BMI of 27 kg/m² or more with at least one weight-related condition (for example hypertension, dyslipidaemia, obstructive sleep apnoea, prediabetes or Type 2 diabetes, PCOS, GORD, NAFLD, osteoarthritis). Ethnicity-adjusted thresholds apply for higher-risk groups.
- When medication cannot be prescribed
Treatment is not prescribed in any of the following: • Pregnancy, planning pregnancy, or breastfeeding • Type 1 diabetes • Current use of insulin or sulfonylureas • Active use of another weight loss medication • Known allergy to the medication or its components • End-stage renal disease or dialysis • Active eating disorder • Severe unstable psychiatric illness • Active inflammatory bowel disease • Severe gastrointestinal disease or gastroparesis • Personal or family history of medullary thyroid cancer (Mounjaro) • MEN2 syndrome (Mounjaro) • Severe unstable retinopathy (Wegovy)
Ready to speak to a GP?
If you feel fully informed, book a consultation to discuss suitability and next steps with one of our GPs.